EF Hutton Acquisition Corp. I (NASDAQ:EFHT) announced this afternoon that it has completed its business combination with E.C.D. Auto Design. Shareholders already approved the deal at a meeting held on December 7.
In connection with last week’s meeting, the company’s stockholders holding 3,470,945 shares, out of a total of 3,492,647 shares of common stock held by stockholders, submitted requests to redeem their shares.
After seeing an aggregate of 99.81% of the trust removed from redemptions (including previous extensions), there are approximately 21,702 shares of common stock held by public stockholders and about $233,000 remaining post-vote.
The newly combined company will be named “ECD Automotive Design Inc.”, and its common stock and warrants will trade on the Nasdaq under the symbols “ECDA” and “ECDAW,” respectively, on Wednesday, December 13.
EF Hutton I announced its $225 million deal with E.C.D. Auto Design in March. Kissimmee, Florida-based E.C.D. Auto Design is the industry leader in delivering restored and modified Land Rover Defenders.
Terms Tracker for the Week Ending February 28, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. With four new IPOs pricing this week, February closes out with eight total IPOs, matching January’s count. That brings the year-to-date total to 16. Interestingly,...
Republic Digital Acquisition Company (NASDAQ:RDAGU) has filed for a $220 million SPAC to hunt for a target in crypto and blockchain technology. The underwriter will be Cantor, which has priced two IPOs so far this year and has four more on file to IPO including Republic Digital. The count of four “on file to IPO” ...
The crop of 13 SPAC sponsors and target companies coming loose from their lock-up agreements this month are representatives of some counter-narrative trends as the two best performing deals are Latin American companies on the eve of new tariffs and the lowest performers are those from the buzzy world of AI software applications. The deal...
Helix II (NASDAQ:HLXB) has entered into a definitive agreement to combine with cancer drug developer BridgeBio at an enterprise value of $360 million. San Francisco-based BridgeBio is developing a trio of potential treatments specifically targeting the KRAS mutation in some lung, breast, pancreatic, and colon cancers. The combined company is expected to trade on the...
At the SPAC of Dawn On a day that the market takes in more Core PCE inflation readings, SPAC watchers also have the chance to peruse the S-1 of yet another former SPAC target that is trying its luck at the traditional IPO path. Drone and aviation firm AIRO Group has not outlined its proposed...